Molecular-targeted therapy has recently begun to be used for SGTCs, and druggable molecular targets in SDC specifically include the androgen receptor, ErbB2/HER-2, BRAF, tumor mutation burden [15], and NTRK gene-fusion, seen in ≥ 80% of salivary gland secretary carcinomas [16]. Here, ERBB2 is linked to neoplasm.